Epic Sciences

Press Releases

11.28.2018

Epic Sciences to Present Data at SABCS 2018

Epic Sciences, Inc. (Epic) announced today that they will be presenting new data on inter- and intra-patient phenotypic heterogeneity and the use of HER2 and AR expression in metastatic breast cancer circulating tumor cells at the 2018 San Antonio Breast Cancer Symposium (SABCS) from December 4 - 8 in San Antonio, TX.

11.05.2018

Epic Sciences Joins Forces with Canadian Consortium of Investigators to Predict Late Recurrence of Metastatic Breast Cancer

Epic Sciences is collaborating with four major breast cancer centers on a clinical trial to determine if Epic’s blood test can be used to predict which women, who have already been treated for localized breast cancer, are at risk of late recurrence of metastatic breast cancer.

10.29.2018

Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castrate Resistant Prostate Cancer, Effective December 10

Medicare coverage supports clinical utility of the Oncotype DX AR-V7 Nucleus Detect test, providing 25,000 Medicare patients with coverage.

09.24.2018

Epic Sciences Announces Publication Showing Blood Test Could Help Select Metastatic Prostate Cancer Patients Who Respond to PSMA-Targeted Therapies

Epic Sciences, in partnership with Memorial Sloan Kettering (MSK), have demonstrated that a liquid biopsy blood test may be used in clinical trials to find patients who are likely to benefit from PSMA-targeted therapies, before treatment is initiated.

09.12.2018

Epic Sciences Announces Completion of $52 Million Series E Financing

Epic Sciences (Epic) announced today that the company has completed a $52 million Series E financing led by Blue Ox Healthcare Partners, with participation by Deerfield Management and Varian (NYSE: VAR).

More Press Releases

In the News

12.12.2018

New Study Reports Blood Test Can Predict Optimal Treatment for Advanced Prostate Cancer

San Diego, Coherent Chronicle — Researchers from Lawson Health Research Institute suggested that a blood test can help predict efficiency of a treatment in advanced prostate cancer. The Lawson Health Research Institute in collaboration with the Memorial Sloan Kettering Cancer Center and the Royal Marsden and Epic Sciences, demonstrated that a blood test can predict the responses of patients suffering from advanced prostate cancer to specific treatments.

12.07.2018

Video - Genomic Sequencing: Precision data to better fight advanced cancer

Portland, KATU2 — Patient Bryce Olson shows the importance of personalized medicine, including the Oncotype DX® AR-V7 Nucleus Detect™ test, in aiding pivotal metastatic castration-resistant prostate cancer treatment decisions. The test, developed by Epic Sciences and commercially available by Genomic Health, is now covered by Medicare.

12.02.2018

Video - PROPHECY Trial: Circulating Tumor Cell as a Biomarker in mCRPC - Andrew Armstrong

San Diego, UroToday — Charles Ryan and Andrew Armstrong discuss the PROPHECY study, a PCF challenge award, co-funded by Movember. Seeing the future with predictive biomarkers was the foundational vision for this study. For men with castration-resistant prostate cancer undergoing a range of therapies, two AR-V7 tests were prospectively compared to see how well they predicted both progression-free survival and overall survival.

11.12.2018

Video - New test extending lives of advanced prostate cancer patients

Bryce Olson discusses the Oncotype DX® AR-V7 Nucleus Detect™ test, developed by Epic Sciences and commercially available through Genomic Health, with ABC 10 News. The test determines which men with late-stage metastatic prostate cancer will benefit from AR-targeted therapy or chemotherapy.

11.06.2018

Blood Test May Identify Cancer Patients Who Respond to PSMA-Targeted Therapies

San Diego, CLP Magazine — In a study sponsored by Epic Sciences, San Diego, in partnership with Memorial Sloan Kettering Cancer Center, researchers have demonstrated that a liquid biopsy blood test may be used before treatment is initiated in clinical trials to find patients who are likely to benefit from therapies targeting prostate-specific membrane antigen.

More News